123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Keyphrases

• 11 September 11%
• 123I-MIBG 82%
• 123I-MIBG Scintigraphy 100%
• 18 Years Old 29%
• 18F-FDG Positron Emission Tomography 100%
• 18F-FDG Positron Emission Tomography/computed Tomography 64%
• Clinical Application 5%
• Clinical Significance 5%
• Clinical Value 5%
• Computed Tomography 11%
• Conference Proceedings 5%
• Confidence Interval 5%
• Diagnostic Accuracy 58%
• Embase 5%
• Embryonic Tumors 5%
• Exclusion Criteria 5%
• Extracranial 5%
• Extracted Data 5%
• False-negative Results 5%
• False-negative Tests 5%
• False-positive Results 11%
• First Diagnosis 29%
• Fluorine-18 5%
• Forest Plot 5%
• Index Tests 5%
• Lesion Level 11%
• Malignant Solid Tumor 5%
• MEDLINE 5%
• Metastasis 41%
• Methodological Quality 5%
• MIBG Scan 11%
• MIBG Scintigraphy 5%
• Neural Crest 5%
• Neuroblastoma 100%
• Neuroblastoma Cells 5%
• Neuroblastoma Tumor 5%
• Ovid 5%
• Patient numbers 11%
• Patient Response 5%
• Patient-level 5%
• Patients Included 5%
• Physiological Uptake 5%
• Positive Test 5%
• Positron Emission Tomography Imaging 100%
• Positron Emission Tomography/computed Tomography Imaging 52%
• Positron Emission Tomography/computed Tomography Scan 5%
• Primary Diagnostics 5%
• Primary Tumor 5%
• Prognosis Treatment 5%
• Response to Therapy 17%
• Review Authors 11%
• Scintigraphy 35%
• Search Methods 5%
• Selection Criteria 5%
• Single Lesion 5%
• Single Test 5%
• Single-photon Emission Computed Tomography (SPECT) 52%
• Skeletal Lesions 5%
• True Positive 5%
• Tumor 17%

Medicine and Dentistry

• (3 Iodobenzyl)guanidine 4%
• Bone Lesion 4%
• Computer Assisted Tomography 13%
• Diagnostic Accuracy 45%
• Diagnostic Test 4%
• False Negative Result 9%
• False Positive Result 9%
• Fluorine-18 4%
• Fluorodeoxyglucose F 18 100%
• Forest Plot 4%
• Ganglioneuroblastoma 100%
• Glucose 4%
• Iodine 123 100%
• Metastatic Carcinoma 31%
• Neural Crest 4%
• Neuroblastoma Cell 4%
• Patient with Neuroblastoma 4%
• Positron Emission Tomography 100%
• Positron Emission Tomography-Computed Tomography 50%
• Primary Tumor 4%
• Recurrent Disease 22%
• Scintigraphy 100%
• Sensitivity and Specificity 9%
• Single Photon Emission Computed Tomography-Computed Tomography 36%
• Single-Photon Emission Computed Tomography 4%
• Solid Malignant Neoplasm 4%
• Tumor 22%